You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB01284
DescriptionA synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex.
Protein structureNo structure small
Related Articles
Protein chemical formulaC136H210N40O31S
Protein average weight2933.437 Da
Download FASTA Format
Adrenocorticotropic hormone 1-24
ATCH (1-24)
Corticotropin-(1-24) tetracosapeptide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CortrosynInjection, powder, for solution.25 mg/mLIntramuscular; Intravenous; ParenteralGeneral Injectables & Vaccines, Inc2010-03-01Not applicableUs
CortrosynInjection, powder, lyophilized, for solution.25 mg/mLIntramuscular; IntravenousAmphastar Pharmaceuticals, Inc.2003-08-01Not applicableUs
Cortrosyn Inj 0.25mgPowder, for solution0.25 mgIntramuscular; IntravenousAmphastar Pharmaceuticals, Inc.1974-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CosyntropinInjection, powder, lyophilized, for solution.25 mg/mLIntravenousSandoz Inc2012-06-29Not applicableUs
CosyntropinInjection, powder, for solution.25 mg/mLIntramuscular; IntravenousMylan Institutional LLC2013-05-08Not applicableUs
CosyntropinInjection, powder, for solution.25 mg/mLIntramuscular; IntravenousMylan Institutional LLC2013-05-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
CAS number16960-16-0
IndicationFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
Structured Indications
PharmacodynamicsCosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N- terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residue. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of Cosyntropin is similar to that of purified natural ACTH. It has been established that 0.25 mg of Cosyntropin will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. Cosyntropin has less immunogenic activity than ACTH because the amino acid sequence having most of the antigenic activity of ACTH, i.e., amino acids 25-39, is not present in cosyntropin. The extra-adrenal effects which natural ACTH and Cosyntropin have in common include increased melanotropic activity, increased growth hormone secretion and an adipokinetic effect. These are considered to be without physiological or clinical significance.
Mechanism of actionCosyntropin combines with a specific receptor in the adrenal cell plasma membrane and, in patients with normal adrenocortical function, stimulates the initial reaction involved in the synthesis of adrenal steroids (including cortisol, cortisone, weak androgenic substances, and a limited quantity of aldosterone) from cholesterol by increasing the quantity of the substrate within the mitochondria. Cosyntropin does not significantly increase plasma cortisol concentration in patients with primary or secondary adrenocortical insufficiency.
TargetKindPharmacological actionActionsOrganismUniProt ID
Adrenocorticotropic hormone receptorProteinyes
HumanQ01718 details
Related Articles
AbsorptionRapidly absorbed following intramuscular administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeAbout 15 minutes following intravenous administration.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Drug Interactions
DrugInteractionDrug group
ClonazepamCosyntropin may increase the hepatotoxic activities of Clonazepam.Approved, Illicit
DiazepamCosyntropin may increase the hepatotoxic activities of Diazepam.Approved, Illicit, Vet Approved
NitrazepamCosyntropin may increase the hepatotoxic activities of Nitrazepam.Approved
PhenobarbitalCosyntropin may increase the hepatotoxic activities of Phenobarbital.Approved
PhenytoinCosyntropin may increase the hepatotoxic activities of Phenytoin.Approved, Vet Approved
PrimidoneCosyntropin may increase the hepatotoxic activities of Primidone.Approved, Vet Approved
Valproic AcidCosyntropin may increase the hepatotoxic activities of Valproic Acid.Approved, Investigational
Food InteractionsNot Available
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesH01AA02
AHFS Codes
  • 68:28.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ManufacturersNot Available
Dosage forms
Injection, powder, for solutionIntramuscular; Intravenous; Parenteral.25 mg/mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous.25 mg/mL
Powder, for solutionIntramuscular; Intravenous0.25 mg
Injection, powder, for solutionIntramuscular; Intravenous.25 mg/mL
Injection, powder, lyophilized, for solutionIntravenous.25 mg/mL
Unit descriptionCostUnit
Cortrosyn 0.25 mg vial127.9USD vial
Cosyntropin 0.25 mg/ml119.91USD ml
Cosyntropin 0.25 mg vial115.1USD vial
Synacthen Depot 1 mg/vial34.77USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Experimental PropertiesNot Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available


Pharmacological action
General Function:
Melanocortin receptor activity
Specific Function:
Receptor for corticotropin (ACTH). This receptor is mediated by G proteins (G(s)) which activate adenylate cyclase (cAMP).
Gene Name:
Uniprot ID:
Molecular Weight:
33926.28 Da
  1. Schwerin M, Kanitz E, Tuchscherer M, Brussow KP, Nurnberg G, Otten W: Stress-related gene expression in brain and adrenal gland of porcine fetuses and neonates. Theriogenology. 2005 Mar 1;63(4):1220-34. [PubMed:15710205 ]
  2. Mehrabani PA, Bassett JR: Adrenocorticotropin binding sites in rat cardiac tissue. Pharmacol Biochem Behav. 1990 Jan;35(1):99-103. [PubMed:2156274 ]
  3. Moraes RB, Czepielewski MA, Friedman G: Cortisol variation after low-dose Cortrosyn test. Crit Care Med. 2010 Jul;38(7):1612-3. doi: 10.1097/CCM.0b013e3181da4ef1. [PubMed:20562554 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
comments powered by Disqus
Drug created on May 23, 2007 21:46 / Updated on August 17, 2016 12:23